Recombinant Human B-lymphocyte antigen CD20(MS4A1)-VLPs (Active)

In Stock
  • 货号:
    CSB-MP015007HU
  • 规格:
  • 图片:
    • Western Blot
      CSB-MP015007HU is detected by Mouse anti-6*His monoclonal antibody.
    • Activity
      Measured by its binding ability in a functional ELISA. Immobilized human CD20 at 2 μg/ml can bind Anti-CD20 recombinant antibody (CSB-RA015007A1HU), the EC50 is 3.243-7.085 ng/mL.
    • The presence of VLP-like structures was confirmed by TEM
  • 其他:

产品详情

  • 内毒素:
    Less than 1.0 EU/ug as determined by LAL method.
  • 生物活性:
    Measured by its binding ability in a functional ELISA. Immobilized human CD20 at 2 μg/mL can bind Anti-CD20 recombinant antibody (CSB-RA015007A1HU), the EC50 is 3.243-7.085 ng/mL.
  • 基因名:
    MS4A1
  • Uniprot No.:
  • 别名:
    (B-lymphocyte surface antigen B1) (Bp35) (Leukocyte surface antigen Leu-16) (Membrane-spanning 4-domains subfamily A member 1) (CD antigen CD20)
  • 种属:
    Homo sapiens (Human)
  • 蛋白长度:
    Full Length
  • 来源:
    Mammalian cell
  • 分子量:
    34.4 kDa
  • 表达区域:
    1-297aa
  • 氨基酸序列
    MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP
  • 蛋白标签:
    C-terminal 10xHis-tagged (This tag can be tested only under denaturing conditions)
  • 产品提供形式:
    Liquid
    Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
  • 缓冲液:
    PBS, pH 7.4, 6% trehalose
  • 储存条件:
    Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
  • 保质期:
    The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
    Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
  • 货期:
    Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 注意事项:
    Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.
  • 产品描述:

    CUSABIO's product CSB-MP015007HU is a recombinant human B-lymphocyte antigen CD20-VLP (virus-like particle). It is produced by the expression of the DNA fragment corresponding to 1-297aa of the human CD20 protein in HEK293 cells. This full-length CD20 protein is fused with a 10xHis-tag at the C-terminus. It has been validated to be active. In the functional ELISA, this recombinant CD20 protein can bind to the anti-CD20 antibody. The EC50 is 3.243-7.085 ng/mL. As a VLP, this recombinant CD20 antigen is highly immunogenic and can induce an immune response similar to a natural infection but fail to replicate in the body. It can be used in cancer studies. And it is available now.

    The CD20 antigen is a hydrophobic transmembrane protein expressed during B cell differentiation from the pro-B cell phase until the plasma cell stadium. It is therefore a marker for B cells. It is co-expressed on B cells with CD19. CD20 plays an essential role in the regulation of B-cell development and differentiation, B-cell receptor (BCR) signaling, and cell cycle initiation.

  • Datasheet & COA:
    Please contact us to get it.

问答及客户评论

 常见问题解答
Q:

Why does the CD20 protein is almost invisible in the tube?

A:

All CUSABIO proteins don't contain carrier protein or other additives, such as bovine serum albumin (BSA), human serum albumin (HSA), and sucrose. When freeze-drying the lowest salt content solution, it often does not form a white grid structure, but a trace amount of protein deposits within the tube, forming a thin transparent or invisible protein layer.

Tips: Before opening the lid, we recommend centrifuging the tube in a small centrifuge for 20-30 seconds to aggregate the protein attached to the inside wall or cap of the tube to the bottom of the tube. Our quality control steps ensure that the amount of protein contained in each tube is accurate. Although sometimes you can’t see the protein powder, the protein content in the tube is still very accurate.

Q:

Does this CD20 protein soluble?

A:

Yes, it is. We offer five expression systems: E. coli, Yeast, Baculovirus, Mammalian cell, and Cell-Free (in vitro E.coli). Among them, yeast only has supernatant expression, and the protein expressed in the supernatant must be a soluble protein.
The E. coli, Baculovirus, Mammalian cell, and Cell-Free (in vitro E.coli) have both supernatant expression and inclusion body expression. As long as the protein is expressed in the supernatant, it must be soluble. If it is expressed in the inclusion body, we will also take a variety of methods to refold it and finally ensure that all the proteins we provide are soluble.

Q:

Why should we add the protective agent to the protein solution before lyophilization? What's the general protective agent? Which kind of protective agent do you usually add?

A:

The protective agent is used in the process of freeze-drying and storage to protect the protein.
Commonly used protective agents or stabilizers include saccharides, polyols, polymers, surfactants, some proteins, and amino acids, etc. We usually add 6% (mass ratio by volume) of trehalose as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure and the extension and aggregation of proteins during freeze-drying process. Mannitol is also a universal applied lyoprotectant and filler, which can reduce the aggregation of certain proteins after lyophilization.

Tips: For the majority of proteins, they can be only stored at 4 ℃ for a short term (about a week) after being resuspended. If you want long-term preservation, they should be formulated as a diluent (which must contain a carrier protein, such as 0.1% BSA, 5% HSA, or 10% FBS), and then repackaged and frozen at -20℃ or -80℃. Be sure to avoid repeated freezing and thawing. Because each freezing and thawing cycle will cause part of the protein inactivation.

Q:

Is the CD20 protein free of animal components?

A:

Yes, it is. We guarantee that all proteins produced by CUSABIO are 100% animal-free, as we do not use any animal components in our raw materials and no animal components are added during the production process. Serum-free media is also used in the expression of our mammalian proteins. We can provide a declaration of no animal component if it is required.

Q:

Is this protein cell-component-free?

A:

The protein expressed in the body, regardless of the system, is expressed by cell, and the cell expression can be divided into intracellular expression and secretory expression.
The E. coli system only has intracellular expression and needs to be broken, so the cell components are relatively more secreted than other systems.
Yeast, Baculovirus, and Mammalian cell systems can be expressed both in the cell and in the secretory expression, and the secreted expression of the protein component remains relatively less intracellular.
In vitro expression means that cell-free and the E. coli cell extract is also added, so that the cell component remains.

Therefore, no matter which expression system and which way the protein is expressed, there will be residual cell components, but we finally use affinity chromatography to purify. In theory, the residual of the cell components will be very small, but 100% of no residue cannot be guaranteed. (Nor does any companies dare to guarantee).

Q:

Can you offer aseptic manufacture processing?

A:

Yes, we can offer an aseptic processing service and it is free of charge, but you should remark this information when placing the order. We've performed aseptic processing for liquid protein before lyophilization, but there may exist contamination during lyophilization process. To clarify, lyophilized proteins can’t guarantee aseptic processing for the whole manufacture process.

Q:

Can you remove the tag?

A:

Not all protein tags can be removed as some proteins will be very unstable after tag removal. Please contact us in advance if you need to remove the tag which takes 2-3 business days. If we succeed in removing the tag, we will charge for extra cost for it. If we fail in removing the tag, we won't charge for any extra cost and remark this information in the datasheet as follows "Note: The laboratory determined that the tag on your protein could not be removed with standard laboratory procedures. Your protein is being supplied with the tag intact."

Q:

What is the concentration range of the protein? How do you determine the quantity of it?

A:

The protein concentration of each batch won't be exactly the same but we could guarantee 0.1-5.0 mg/mL concentration for our expression system. If you have a special requirement for protein concentration, please contact us in advance.

There are three methods of protein concentration detection: bradford method, BCA method, A280 method. Each of these three methods has interference buffer components. According to the composition of buffer, the bradford method is the most popular with laboratories including ours, and the concentration detection range is 0.1-5 mg/mL. We also use BCA method in times.

靶点详情

  • 功能:
    This protein may be involved in the regulation of B-cell activation and proliferation.
  • 基因功能参考文献:
    1. Our study found that a small subset of papillary thyroid carcinomas (<10%, mainly of classic variant) exhibited aberrant membranous expression of CD20 PMID: 29079175
    2. Our results support the fact that CD200 can be added to routine Chronic lymphoproliferative disorders panel as it is useful in subcategorizing them. However, inclusion of CD20 ABC to routine panel does not seem plausible but may be done for difficult diagnostic cases or where anti-CD20 therapy is planned. PMID: 29567884
    3. showed here that 3' UTR NOTCH1 mutations are associated with low CD20 expression and with relative resistance to anti-CD20 immunotherapy in vitro PMID: 28550186
    4. We conclude that the relationship between complement-regulatory proteins CFHR1 and CFHR3 and response to anti-CD20 mAb therapy varies based on the specific anti-CD20 mAb used. PMID: 27528699
    5. Limiting the antibody-induced induction of immunosuppressive reactive oxygen species may improve the anti-leukemic efficacy of anti-CD20 therapy in chronic lymphocytic leukemia. PMID: 27097113
    6. Case Report: primary cutaneous T-cell lymphoma with aberrant CD20 expression. PMID: 27840885
    7. Data suggest that insulitis (destruction of pancreatic beta-cells and their ability to produce/secrete insulin) occurs in two distinct profiles in type 1 diabetes; these differ in proportion of CD20-positive B-lymphocytes (relative to CD4-positive T-lymphocytes) present within the infiltrate; greater infiltration of CD20-positive B-lymphocytes leads to more aggressive disease progression. PMID: 26858360
    8. PZ-DHA also arrested MDA-MB-231 cell division at the G2/M phase and down-regulated expression of cyclin B1 and cyclin-dependent kinase 1 (CDK1) PMID: 27535497
    9. there is a high CD23a/CD23b ratio of chronic lymphocytic leukemia cells, which demonstrates that in a subset of CLL cases, low CD23 expression together with high CD20 and CD38 expressions may serve as a surrogate for trisomy 12 PMID: 26119874
    10. IL-17-producing pathogenic T lymphocytes co-express CD20 in primary Sjogren's syndrome patients. PMID: 26814615
    11. Studies indicate that CD20 antigen expression is absent in a variety of diffuse large B cell lymphomas (DLBCLs), including plasmablastic lymphoma, primary effusion lymphoma, anaplastic lymphoma, kinase-positive DLBCL, and large B cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease. PMID: 26459310
    12. lipid formulations based on a polyplex or lipoplex backbone additionally equipped with anti-CD20 antibodies are promising non-viral vectors for specific oligonucleotide transfer into human tumor cells. PMID: 26585505
    13. The ABC values obtained for CD20 expression levels using PE, APC, or PerCP Cy5.5 are consistent over the five different instrument platforms for any given apparently healthy donor independent of the fluorochrome used PMID: 26013593
    14. Data indicate that Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) patients who presented with cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) deletion showed a higher rate of CD20 antigen expression. PMID: 27090891
    15. the findings demonstrate that treatment with anti-CD20-hIFNalpha reverses resistance of B-NHL PMID: 26398317
    16. Case Report: aberrant CD20 expression by skin-infiltrating T cells using multispectral imaging. PMID: 26381030
    17. Microenvironment CD20 + cells seem to play a favorable prognostic role in classical Hodgkin Lymphoma. Depletion of CD20 + cells together with an increase of TAMs identifies a group of patients with high-risk disease. PMID: 25098425
    18. In conclusion, SNPs of CD20 were not high risk factors of DLBCL, but the T allele of rs2070770 was a potential indicator of superior survival. PMID: 24898664
    19. Characterize premature human NK/T-cell lymphoma cell line with expression of the B-cell marker CD20. PMID: 26299072
    20. Data indicate that CD20 antigen downregulation relies on transcriptional mechanisms in SRC family kinases (SFKs)-dependent transcriptional regulation of CD20. PMID: 25517315
    21. This study identified a novel D393-CD20-derived MHC Class II restricted epitopes that bind various HLA-DR alleles. IFN-gamma-producing D393-CD20 specific CD4 T cell responses were detected in blood lymphocytes from lymphoma patients and D393-CD20 specific CD4 Th1 clones were able to recognize both lymphoma cell lines and autologous lymphoma cells and to induce their apoptosis. PMID: 25449106
    22. Letter/Review: Liver transplant recipients developing CD20-positive lymphoproliferative lesions are significantly older at time of transplantation. PMID: 25394454
    23. CD20 in multiple myeloma without the t(11;14) may have a role in poor prognosis and aberrant expression of Wnt signaling PMID: 24408089
    24. in two cases of mycosis fungoides, CD20 was expressed by a significant population of the neoplastic T-cells, but these T-cells lacked expression of other B-cell markers, including CD79a, CD19 and PAX5. PMID: 24467775
    25. Data indicate that depletion of CD20-expressing T cells may also contribute to the therapeutic effect of rituximab (RTX). PMID: 24928997
    26. Significantly lower rates of CD20 B cells were found in women with placental malaria infections compared with those without such infections. Neither placental malaria infection nor CD20 are associated with low birth weight. PMID: 24245949
    27. Expansion aggregation of CD20+ B cells, HLA-DR expression and arteriolar hyaline thickening influence the outcome of acute cellular rejection in renal allograft. PMID: 23428174
    28. Patients whose percentage of CD20 antigen was above 60.3% had longer treatment-free survival. PMID: 23659384
    29. CD20 protein was aberrantly expressed in T-mycosis fungoides lesions PMID: 24145652
    30. MS4A1/CD20 is responsible for TGF-beta-induced apoptosis of B-cell lymphoma cells. Moreover, downregulation of MS4A1/CD20 by TGF-beta attenuated the effects of the monoclonal anti-MS4A1/CD20 antibody, rituximab, on Ramos cells. PMID: 22665052
    31. Anti-hCD20 IgE antibodies have in vitro cytotoxic activity. PMID: 22692757
    32. Case Report: CD20-positive NK/T-cell lymphoma with an indolent clinical course. PMID: 23031227
    33. CD20 antigen is not expressed in cancer stem cells in multiple myeloma. PMID: 22315496
    34. CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value. PMID: 22664043
    35. Data indicate that the bridging of CD20 antigen and FcgammaRIIIa is an essential interaction for the initiation of antibody dependent cell-mediated cytotoxicity (ADCC) activity and assay. PMID: 22914441
    36. CD20-positive posttransplant lymphoproliferative disorder lesions in kidney transplant patients are significantly more likely to develop early after transplant and represent an inferior outcome. PMID: 22758374
    37. Data show that in the blood of rheumatoid arthritis (RA) patients, a greater proportion of Th17 cells are of a CD20+ phenotype compared to healthy individuals, suggesting these cells may represent an additional target for anti-CD20 therapies. PMID: 22171710
    38. Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity PMID: 22843692
    39. Dsta show that differential expression of MS4A1 is a stromal signal of uncertain significance, and an example of the rationale for tumor cell enrichment in preparation for gene expression studies to identify markers of particular tumor phenotypes. PMID: 22514692
    40. Report disappointing results after long term treatment of lupus nephritis with anti-CD20 antibody rituximab. PMID: 21258801
    41. B-cell depletion induces transient aggressive behavior in BDC2.5 diabetogenic T cells and reduction in regulatory T (Treg) cell number and function during the B-cell depletion period. PMID: 22490442
    42. Defects in CD20/ B-cell receptors signalosome conformation might predispose to the spectrum of common variable immunodeficiency disorders. PMID: 22130422
    43. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. PMID: 22517865
    44. Results suggest for the clinical utility of CD20-specific T cells in B cell malignancies. PMID: 21630262
    45. Case Report: obtained good results in 2 high-titer ABO-incompatible living donor kidney transplantation using anti-CD20 and anti-CD25 antibodies without splenectomy, in conjunction with a calcineurin inhibitor plus mycophenolate mofetil or mizoribine. PMID: 21839272
    46. Using protein tomography, different CD20 complexes were found to be associated with the 2 antibodies, and confocal microscopy showed different membrane compartmentalization of these subpopulations of the cellular CD20 pool. PMID: 21444918
    47. The neoplastic epithelial cells in cases of type A and type AB thymoma, as well as few cases of type B1 and B2 thymoma, express CD20. PMID: 21092589
    48. Adoptively T cells transduced anti-CD20scFvFc/CD28/CD3zeta gene mediates enhanced anti-tumor activities against CD20 positive tumor cells, suggesting a potential of gene-based immunotherapy for non-Hodgkin lymphoma. PMID: 20815894
    49. Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. PMID: 20674973
    50. CD20 immunoexpresion in early rheumatoid arthritis synovium. PMID: 20191119

    显示更多

    收起更多

  • 相关疾病:
    Immunodeficiency, common variable, 5 (CVID5)
  • 亚细胞定位:
    Cell membrane, Multi-pass membrane protein, Cell membrane, Lipid-anchor
  • 蛋白家族:
    MS4A family
  • 组织特异性:
    Expressed on B-cells.
  • 数据库链接:

    HGNC: 7315

    OMIM: 112210

    KEGG: hsa:931

    STRING: 9606.ENSP00000314620

    UniGene: Hs.712553